Tenderwize
Retour à la recherche

Open-House-Biologika-Rabattverträge 2026-07 - Tocilizumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 30, 2028 · 613 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-07 - Tocilizumab

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The notice explicitly states this is not a public procurement under EU law; legal remedies lie with social courts, not...

No estimated value; potential volume unclear.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of discount agreements for the active substance Tocilizumab (pharmaceutical products)
Afficher le résumé complet

Open-house procedure for pharmaceutical discount agreements for Tocilizumab under §130a Abs. 8 SGB V. Techniker Krankenkasse and other German health insurers invite any qualified pharmaceutical entrepreneur to conclude a standard discount agreement. No competitive selection; all eligible participants can join anytime during the contract period (May 2026 - April 2028). Submission by email with qualified electronic signature or by post.

Risques

The notice explicitly states this is not a public procurement under EU law; legal remedies lie with social courts, not...

No estimated value; potential volume unclear.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG
  • Must have valid marketing authorization for the medicinal product
  • Must have seat in Germany, EU, or EEA

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2026-07 - Tocilizumab

Conclusion of discount agreements for the active substance Tocilizumab under an open-house procedure. Uniform conditions, no exclusivity, maximum contract period 24 months.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 30, 2028

Détails de la procédure

Date de publication
18 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
190657-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3